Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) for the Treatment of IDH1-Mutated…
Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced the U.S. Food and Drug Administration (FDA) has approved TIBSOVO…
Read More...
Read More...